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Pharmacy, Portland, MaineABSTRACT The extracellular carbohydrate-binding domain of the Type I transmembrane receptor CD44 is known to undergo
affinity switching, where change in conformation leads to enhanced binding of its carbohydrate ligand hyaluronan. Separate
x-ray crystallographic and NMR experiments have led to competing explanations, with the former supporting minor conforma-
tional changes at the binding site and the latter a major order-to-disorder unfolding transition distant from the binding site. Here,
all-atom explicit-solvent molecular dynamics studies employing adaptive biasing force sampling revealed a substantial favorable
free-energy change associated with contact formation between the Arg41 side chain and hyaluronan at the binding site, indepen-
dent of whether the distant site was ordered or disordered. Analogous computational experiments on Arg41Ala mutants showed
loss of this favorable free-energy change, consistent with existing experimental data. More provocatively, the simulation data
revealed the molecular mechanism by which the order-to-disorder transition enhances hyaluronan binding: in the disordered
state, a number of basic residues gain sufficient conformational freedom—lacking in the ordered state—to spontaneously
form side-chain contacts with hyaluronan. Mutation of these residues to Ala had been known to decrease binding affinity, but
there had previously been no structural explanation, given their lack of proximity to the carbohydrate-binding site in existing
structures of the complex.INTRODUCTIONCD44 is a Type-I transmembrane protein expressed on a
large variety of human cells, including normal leukocytes
as well as cancer cells having invasive/metastatic pheno-
types (1–4). The gene encoding human CD44 consists of
19 exons (5). Variable splicing of exons 6–14 (commonly
referred to as ‘‘v2-v10’’) in the middle of the CD44
gene yields a variety of different protein forms, with vary-
ing functions and tissue associations (6–8). The standard
splice variant CD44s is characterized by a lack of these
v-exons, resulting in a 341-residue protein after cleavage
of a 20-residue N-terminal signal peptide, with residues
21–268 located on the extracellular side of the membrane,
the next 22 composing the transmembrane helix, and
the final 71 located on the cytosolic side. The first 158
residues of CD44s, which are conserved across other splice
variants, compose a globular extracellular domain (9) that
is capable of binding the linear carbohydrate polymer
hyaluronan (HA) (10) and that is attached to the trans-
membrane helix by a 90-residue membrane-proximal
stalk region. This globular hyaluronan binding domain
(HABD) has been extensively characterized both func-
tionally and structurally (9–15), and, importantly, retains
its capacity to bind hyaluronan when experimentally ex-
pressed as a model construct lacking the remaining 183
C-terminal amino acids of the complete transmembrane
CD44s protein (16).Submitted April 3, 2013, and accepted for publication July 1, 2013.
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0006-3495/13/09/1217/10 $2.00Hyaluronan, a natural carbohydrate ligand for CD44
HABD, is a linear polymer that can reach sizes exceeding
106 Da (17). The sequence for HA is quite simple and
consists of repeating glucuronic acid-N-acetylglucosamine
dimers (specifically, [-b(1,4)-GlcUA-b(1,3)-GlcNAc-]) (18).
Unlike other related linear carbohydrate biopolymers (e.g.,
heparin), HA is composed exclusively of this dimer repeat,
and is not modified by sulfation (18). Thus, in addition to
being biologically important with regard to normal immune
cell function and cancer cell invasiveness/metastasis, the
CD44:HA binding interaction provides an excellent model
system for studying protein:carbohydrate molecular recog-
nition because of the relative simplicity of the carbohydrate
polymer ligand.
Before the elucidation of the atomic-resolution structure
of HABD, mutational studies demonstrated the importance
of the basic amino acids Arg and Lys in HABD for HA bind-
ing (10). This made physicochemical sense, as the positive
side chains of these residues would be expected to have
favorable electrostatic interactions with HA, in which every
other monosaccharide component is a negatively charged
glucuronic acid residue. In particular, Arg41 was found to
be critical for HA binding, such that an Arg41Ala mutation
eliminated binding (10); this observation has been repeat-
edly confirmed (14,19).
In a pioneering contribution to understanding the molec-
ular basis for CD44:HA binding, Banerji et al. (14) solved
the atomic-resolution structure of a hyaluronan 8-mer
(HA8; 4 dimer repeats) bound to mouse CD44 HABD.
From this work, a structural explanation was immediatelyhttp://dx.doi.org/10.1016/j.bpj.2013.07.041
1218 Favreau et al.apparent for the importance of Arg41 that results from its
location in a loop adjacent to the HA binding site. The com-
plex was crystallized in two forms:
1. In the A crystal form, there is no direct Arg41:HA contact
(note: Arg45 in mouse HABD is the equivalent of Arg41
in human HABD; throughout this text, the human
numbering is used).
2. In the B crystal form, a small conformational change in
the Arg41-containing loop allows for direct contact (spe-
cifically, the change allows for a 6 A˚ displacement of the
Arg41 side-chain guanidinium central Cz atom, which
enables hydrogen bonding between the Arg41 side chain
and bound HA8 (Fig. 1) to match specifically.
A previous crystal structure of human HABD lacking
bound HA had the Arg41-containing loop in the A-form
conformation (9). The presence of the B-form only in the
context of bound hyaluronan therefore implied the impor-
tance of direct Arg41:HA contact for binding, and suggested
that this conformational change might contribute to func-
tional switching between low- and high-affinity states of
CD44 for HA (14,20). However, this structural biology
work did not provide quantitative thermodynamic evidence
for the stabilizing effect of contact formation, and therefore
affinity switching, associated with an A-to-B transition
in mouse HABD when HA is bound. Nonetheless, this
structural explanation is biophysically reasonable. It is
also applicable to human HABD, because there is 88%Biophysical Journal 105(5) 1217–1226amino-acid sequence identity between the mouse (14) and
human (9) structures, and, of the 18 residues which differ,
only two are within 5 A˚ of bound HA8 in the mouse
co-crystal, and only one is within 3 A˚ (see Fig. S1 in the
Supporting Material). Additionally, this latter residue is
located at the reducing end (i.e., GlcNAc1) of bound
HA8, which in simulations of the mouse complex is seen
to spontaneously dissociate (21). In contrast, all HABD
residues that make up the pockets that house GlcNAc3
and GlcUA4, which from these prior simulations are the
most tightly bound of HA8, are conserved between the
two species (see Fig. S1).
NMR experiments have provided an apparently com-
peting structural explanation for affinity switching. In these
experiments, the binding of HA oligomer was associated
with chemical shifts consistent with a large conformational
transition from an ordered (O) form to a partially disordered
(PD) form that involves unfolding of the 17 C-terminal res-
idues of HABD that make up the b9 strand and a3 helix in
the O state (Fig. 2) (13). Additional data from whole-cell
experiments supported this mechanism of affinity switch-
ing, in which the O-to-PD transition is associated with
increased HA-binding affinity (15). In addition, early
work involving truncation mutants clearly demonstrated
that deletion of these C-terminal residues reduces binding
affinity (10). However, the structural and thermodynamics
binding data did not provide a molecular mechanism for
how affinity switching occurred, because the residues thatFIGURE 1 The Arg41-containing loop in
A-form and B-form HABD:HA8 complexes. (a)
A-form. (b) B-form. Arg41 and HA8 are depicted
as van der Waals (vdW) spheres colored by atom
type, and the protein is represented as ribbons,
with loop residues colored by secondary structure.
(Blue arrows) Arg41 side chain. Coordinates are
from x-ray crystallographic mouse HABD:HA8
complexes (14). (c) A-form and B-form complexes
are overlaid. (Pink) A-form loop and Arg41 atoms.
FIGURE 2 Ordered (O) and partially disordered
(PD) states of HABD bound to HA8. (a) O-state.
(b) PD-state. HABD secondary structure is repre-
sented as ribbons with residues 153–169, which
undergo the O-to-PD transition, in color. (Red
arrows) Residue 153; (blue arrows) Residue 169.
HA8 and Arg41 are represented as vdW spheres
colored by atom type, and the Arg41-containing
loop is in the A-form in both instances. Structures
are from early MD simulation snapshots of human
HABD:HA8 complexes constructed using crystal-
lographic and NMR atomic-resolution structures
as detailed in Methods. Note the large distance
separating residues 153–169 from HA8.
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determined via crystallography (Fig. 2). Additionally, in
apparent conflict with these data, in both the A- and
B-form crystal complexes with HA8 these residues are
only in the O conformation with intact secondary structure
(14), as also observed in structures of apo HABD both
from x-ray and NMR experiments (9).
Thus, missing from the x-ray crystallographic description
of affinity switching is the thermodynamics associated with
the A-to-B conformational change of the Arg41 loop,
whereas missing from the NMR description of affinity
switching is a structural molecular mechanism for HABD:
HA interactions arising from the O-to-PD transition. Toward
filling these gaps and understanding whether or not these
two different mechanisms are in some way coupled, we
have performed extensive all-atom explicit-solvent molecu-
lar dynamics (MD) simulations employing the adaptive
biasing force (ABF) free-energy methodology on a variety
of human HABD:HA8 complexes. With regard to the
x-ray description, the MD data clearly show a large favor-
able free-energy change associated with formation of the
direct Arg41:HA interaction in going from A-form to
B-form. Additionally, in Arg41Ala constructs, this large
favorable free-energy change is lost. Combined, these data
clearly demonstrate the importance of the direct side-chain
contact resulting from the A-to-B transition for affinity
switching. With regard to the NMR description, sponta-
neous formation of direct contact between the side chains
of basic residues in the disordered region of HABD with
HA is observed, leading to a simple description of additional
binding affinity arising from direct contact. This apparently
new molecular observation also is consistent with the first-
reported mutation studies in which alanine scanning of these
basic residues was demonstrated to reduce binding affinity,
although not to the same extent as the Arg41Ala mutation
(10). We note that the free energy change of the A-to-Bloop transition is independent of whether HABD is in the
O or PD state, pointing to a lack of allosteric coupling
between the two different affinity-switching molecular
mechanisms.METHODS
System construction
Because of the lack of experimental human HABD:HA structures, such
structures had to be constructed using experimental apo human HABD
structures and experimental mouse HABD:HA structures. An A-form,
ordered human HABD:HA8 complex was constructed by starting with a
crystal structure of apo A-form, ordered human HABD (Protein Data
Bank (PDB), PDB:1UUH) (9). The selenomethionine residues at positions
63 and 66 in the apo human HABD PDB entry were reverted to their bio-
logical Met63 and Met66 identities. The coordinates were then refined using
the REDUCE program (22) to optimize side-chain flip states and His pro-
tonation, resulting in protonation of His35 and His85 at the ε-position and
His92 at the d-position. The apo human HABD structure was aligned
with the A-form, ordered mouse HABD:HA complex (PDB:2JCQ) (14)
using the STAMP structural alignment algorithm (23) as implemented in
the MultiSeq module (24) of the VMD visualization and modeling software
(25). After alignment, HA8 atoms from the mouse structure were spliced
with the human HABD atoms, with the crystallographically unresolved
nonreducing end GlcUA residue built using the same glycosidic linkage
dihedral angle values as the other GlcUA-b(1,3)-GlcNAc linkages in the
HA8 structure and consistent with NMR studies of unbound oligomeric
hyaluronan (26).
An A-form, partially disordered human HABD:HA8 complex was con-
structed by starting with an NMR structure of partially disordered human
HABD, whose coordinates had been solved in the context of bound hyalur-
onan oligomer but for which the binding pose of hyaluronan remained
unknown (PDB:2I83) (13). This structure is deposited in the PDB as an
ensemble of 20 models. Model 18 was chosen for system construction
because it had the lowest root-mean-square (RMS) deviation relative to
PDB:1UUH for the nonhydrogen atoms of residues 42, 77, 78, 79, 88,
96, 97, and 98, which are the residues within 4 A˚ of GlcNAc3 and GlcUA4
in bound HA8. These two monosaccharides have been shown to be the most
tightly-bound of the eight HA8 monosaccharides in previous simulations of
mouse HABD:HA8 complexes (21), thus the selected protein residuesBiophysical Journal 105(5) 1217–1226
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face. Model 18 was optimized with REDUCE as described above, with the
exception that the above-determined His protonation states were enforced
for consistency. Subsequently, HA8 from the above A-form, ordered
complex was spliced with the Model 18 HABD coordinates after RMS
alignment using the stated residues. Additionally, coordinates from the
A-form Arg41-containing loop (residues 38–44) of the above ordered
construct were used to replace those in the partially disordered construct
after RMS alignment of the two using backbone atoms from residues 35–
37 and 45–47. There was substantial variability in loop conformation across
the 20 NMRmodels, thus this loop-splicing was done to ensure comparable
representation of the A-form loop conformation in the ordered and partially
disordered systems.
Visual inspection of both of the new constructs—A-form, ordered (O)
human HABD:HA8 and A-form, partially disordered (PD) human
HABD:HA8—showed good positioning of HA8, with contacts for
GlcNAc3 and GlcUA4 similar to those in the experimental mouse com-
plexes. Using the CHARMM software (27,28), each complex was solvated
in a cube of water molecules having the experimental density of water and
having an edge length of 74 A˚, which was of sufficient size to ensure a
water layer of at least 10 A˚ on each side of the PD form after alignment
of its principal axes along the x, y, and z dimensions. Water molecules
overlapping protein or carbohydrate atoms were deleted, and nine
randomly selected water molecules were replaced with nine sodium ions
to yield net system charges of 0; the two final systems contained ~37,000
atoms each.Simulation details
Systems were represented using the CHARMM protein (29,30) and carbo-
hydrate (31–33) force fields and a modified version (34) of the rigid TIP3P
water model (35). Molecular dynamics simulations were done with the
CHARMM software (28) and with the NAMD software (36). The SHAKE
(37), RATTLE (38), and SETTLE (39) constraint algorithms were used to
constrain bonds involving hydrogen atoms to their equilibrium lengths and
to maintain rigid water geometries. Nonbonded interactions were truncated
at 10 A˚. The particle-mesh Ewald method (40) was used to account for elec-
trostatic interactions beyond this cutoff distance, an isotropic correction
(41) was applied to account for Lennard-Jones interactions beyond the cut-
off, and a switching function (42) was applied to Lennard-Jones interactions
in the 8–10 A˚ range. Isotropic constant pressure of 1 atm was maintained
using the Langevin piston barostat (43), a constant temperature of 310 K
was maintained using Nose´-Hoover (44,45) (CHARMM) or Langevin ther-
mostating (41) (NAMD), and the equations of motion were integrated using
a 2.0-fs timestep and the leap-frog (46) (CHARMM) or BBK (47) (NAMD)
integrator.Generation of initial conditions
Generation of initial conditions to seed free-energy simulations of the
A-to-B transition involved two steps:
Step 1. Unrestrained MD simulations of the above systems; and
Step 2. Use of the final conformations from unrestrained MD as starting
points to generate initial conditions along the reaction coordinate by
using biased MD.
Details of this protocol are:
After a brief minimization and restrained heating/equilibration, the O
and PD systems were each simulated five times in the absence of any
restraints; each simulation was run for 10 ns and used a different random
seed to generate a different trajectory. A single final conformation was
selected—one for O and one for PD—from each of the two sets of
simulations, with the selection based on the conformation having the
lowest RMS deviation for the GlcNAc3 and GlcUA4 atoms after RMSBiophysical Journal 105(5) 1217–1226alignment of the protein atoms in the snapshot with respect to the starting
structure.
The final conformation was used to seed a simulation in which a har-
monic biasing potential was applied to the Tyr42 f backbone dihedral.
The equilibrium value for this biasing potential was gradually increased
by 10 every 12 ps to generate snapshots along a previously determined
reaction path for the A-to-B transition (21). These snapshots served as
initial conditions for the free energy simulations.
Step 1 above was performed using NAMD and Step 2 using CHARMM.
In addition to initial conditions for the wild-type O and PD systems, initial
conditions for Arg41Ala mutants were also generated. This was done with
the CHARMM software by taking the corresponding wild-type initial con-
dition, replacing the Arg41 side chain with a methyl group, and adding an
additional sodium cation to maintain charge neutrality.Free-energy simulations
Free-energy simulations of the A-to-B transition were performed using the
ABF (48–50) methodology as implemented in NAMD ver. 2.8. ABF was
applied to two independent scalar progress variables (reaction coordinates)
simultaneously, which were chosen based on their ability to represent the
Arg41-containing loop conformation (i.e., A versus B) and whether the
Arg41 side chain was directly interacting with HA8. The former progress
variable was simply the Tyr42 f-backbone dihedral, based on prior work
(21). The latter was defined as the distance separating the Arg41 side-chain
guanidinium central Cz atom and the ether oxygen atom in the glycosidic
linkage connecting GlcNAc3 to GlcUA4, with these atoms chosen based
on the Arg41:HA8 close-contact observed in the B-form co-crystal (14).
Minimum and maximum limits of regions sampled for these reaction
coordinates, referred to as f and r subsequently, were based on prior
work (21). Bins for ABF sampling were 5  0.2 A˚. The computed biasing
force for a particular bin was not applied until 50 force samples had been
collected for that bin, after which point the biasing force was linearly
ramped until it reached its full value once 100 force samples had been
taken.
A restraint was applied between the binding site and HA8 to prevent
spontaneous dissociation of HA8 observed in the absence of this
restraint. The restraint consisted of a harmonic potential between the center
of mass for HABD residues 76–79 and 94–97 and the center of mass of
HA8 GlcNAc3 and GlcUA4, with the exclusion of the glycosidic oxygen
connecting them. This exclusion was required because this oxygen atom
is involved in the definition of one of the ABF reaction coordinates. For
the same reason, bonds to hydrogen atoms for which the nonhydrogen
atom was involved in one of the ABF reaction coordinates (specifically,
the hydrogen atoms attached to the Ca and peptide-bond N atoms in
Tyr42 f) were not constrained, and these hydrogen atom masses were set
to 12 amu to allow use of the 2.0-fs integration timestep. Interatomic har-
monic restraints were applied to prevent rupture of hydrogen bonds
between Tyr42 side-chain O and Tyr79 side-chain H and between Tyr42
side-chain hydroxyl H and GlcNAc3 carbonyl O. The above harmonic
restraints were used to maintain the structural integrity of regions of the
system that, from the x-ray structures, are unchanged in going from the
A-form to the B-form, and equilibrium values for these restraints were
determined accordingly. In addition, we emphasize that none of the atoms
involved in these restraints overlapped with atoms used to define the ABF
progress variables. The utility program ABF_INTEGRATE provided with
the NAMD Ver. 2.8 distribution was used to integrate the average forces
from ABF sampling to yield free energy as a function of the two reaction
coordinates.
A similar protocol was used for the Arg41Ala mutant systems, with the
Ala41 side-chain Cb atom being used to define r, analogous to the Arg41
side-chain Cz atom in the wild-type simulations.
Table S1 in the Supporting Material contains the full listing of the initial
conditions for the four free-energy simulations. Each initial condition
served as the starting point for a 200-ns ABF simulation.
FIGURE 3 A-to-B form transition free energies for HABD:HA8
complexes from ABF simulations. (a) Wild-type, ordered HABD.
(b) Wild-type, partially disordered HABD. (c) Arg41Ala, ordered HABD.
(d) Arg41Ala, partially disordered HABD. The free-energy scales are in
kcal/mol.
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The A-to-B transition strongly stabilizes the
HABD:HA complex
X-ray crystallographic structural biology provides strong
support for the hypothesis that the A-to-B transition
(Fig. 1) ought to be involved in switching the HABD:HA
binding interaction from a low-affinity state to a high-
affinity one, because this transition results in the formation
of direct hydrogen bonding between the Arg41 side chain
and HA8 (14). Furthermore, the observed interaction is
consistent with the large effect an Arg41Ala mutation has
on reducing binding affinity (10,14,19). The results of the
present free-energy simulations are, to our knowledge, the
first direct evidence demonstrating that the A-to-B structural
transition is indeed thermodynamically stabilizing, thereby
linking the existing atomic-resolution structural data with
the existing point-mutation binding data.
The structural differences between the A-form and
B-form of the HABD:HA complex can be represented by
a combination of two reaction coordinates (21) (defined in
Methods):
1. f, which refers to the value of the Tyr42 f backbone
dihedral, and
2. r, which represents the distance between the Arg41 side-
chain guanidinium moiety and the GlcNAc3 and
GlcUA4 residues in HA8.
The A-form is characterized by a negative value of f and
a large value of r and the B-form by a positive value of f and
a small value of r.
In Fig. 3, with f plotted on the horizontal axis and r on the
vertical axis, MD snapshots corresponding to the A-state
occupy the upper-left region and those corresponding to
the B-state occupy the lower-right region of the plot.
Fig. 3, a and b, shows results of ABF free-energy simula-
tions of the wild-type HABD:HA8 interaction. These
results demonstrate that the protein:carbohydrate binding
is strongly stabilized by the A-to-B structural transition
that results in direct contact of the Arg41 guanidinium
with GlcNAc3 and GlcUA4. Data are presented for both
the ordered (Fig. 3 a) and partially disordered (Fig. 3 b)
forms of human HABD, and in both cases, there is a prom-
inent global minimum at f ¼ 60 and r ¼ 4 A˚, correspond-
ing to the B-form. Also, in both cases, there is a prominent
local minimum at f¼ 60 and r¼ 14 A˚, corresponding to
the A-form. The transition state for the A-to-B transforma-
tion is in the region 30 < f < 0.
The overall shape of the free-energy plots and location of
these minima is consistent with previous work on ordered
mouse HABD:HA8, though those previous results sug-
gested that the A- and B-forms were of similar free energy
(21). In that earlier study employing umbrella sampling,
biasing was applied only to the f-coordinate, and the
Arg41 side chain:HA8 contact distance was not biased;furthermore, the timescale of that study was limited to
5 ns per simulation window, compared to the 200-ns time-
scale used in this article. Thus, the significant stabilizing
effect of the A-to-B transition noted here likely represents
the use of more sophisticated sampling methodology com-
bined with a 40 increase in sampling time per window,
as opposed to a significant species-dependent difference
between the human and mouse isoforms of CD44 HABD
given the very high homology between the two, as detailed
in the Introduction and in Fig. S1. That said, in the absence
of similar data for the mouse system, a species-dependent
difference cannot be ruled out, and it should be noted that,
in contrast to mouse HABD, efforts at crystallizing human
HABD:HA8 complexes have been unfruitful (14).The O-to-PD transition does not affect Arg41
stabilization of the B-form complex
The computed free energies of the A-to-B transition for
ordered versus partially disordered wild-type human
HABD are notable for their similarity. From the ABF data
(Fig. 3, a and b), the major minima are in the same
place—f ¼ 60 and r ¼ 14 A˚ for the A-form and f ¼
60 and r ¼ 4 A˚ for the B-form—and the free-energy dif-
ference between the A-form and B-form regions is nearly
identical. Table 1 summarizes the exact locations of theBiophysical Journal 105(5) 1217–1226
TABLE 1 Locations (f, r) of free-energy minima and DGA-to-B values
Free-energy simulation A-form minimuma (, A˚) B-form minimumb (, A˚) DGA-to-B
c (kcal/mol)
Wild-type, ordered 57.5, 14.3 57.5, 4.1 8.7
Wild-type, partially disordered 62.5, 14.3 57.5, 4.1 7.8
Arg41Ala, ordered 62.5, 10.1 57.5, 8.1 6.5
Arg41Ala, partially disordered 57.5, 10.1 57.5, 7.9 5.5
aDefined as the 5  0.2 A˚ bin with the lowest free-energy value and having f < 15 and r > 14 A˚ for wild-type simulations and f < 15 for Arg41Ala
simulations.
bDefined as the 5  0.2 A˚ bin with the lowest free-energy value and having f > 15.
cDefined as the free-energy value of the B-form minimum minus that of the A-form minimum.
1222 Favreau et al.minima in Fig. 3, a and b, and the DGA-to-B values calculated
using these minima. For the transition in the ordered system,
the value is 8.7 kcal/mol, and in the partially disordered
system, the value is 7.8 kcal/mol. Based on time-depen-
dent estimates of error (see below), the DDG of 1 kcal/
mol between these two values is on the order of the error
in the calculation. Thus, given a precision of ~1 kcal/mol,
the free-energy change for the A-to-B transition is indepen-
dent of whether the system is in the O or PD state.
Therefore, within the precision of the computational exper-
iment, there does not appear to be favorable allosteric
coupling between the A-to-B transition at the binding site
and the O-to-PD transition away from the binding site.
These DGA-to-B results therefore leave unresolved how to
explain the experimental observation that the O-to-PD
transition is coupled to the binding of hyaluronan (13,15);
the explanation for the experimental observation comes
only after additional analysis of the MD trajectories, as
detailed next.C-terminal residues are rigid in the wild-type
O-form and highly flexible in the PD-form
Generation of the free-energy data (Fig. 3, a and b) involved
five separate 200-ns ABF MD simulations for ordered
HABD and six separate simulations for partially disordered
HABD (see Table S1). Each of these independent trajec-
tories was separately analyzed to determine the relative flex-
ibility of the residues in the protein.
Both the O and PD states exhibit similarly low flexibility
from the N-terminus to residue 150 (see Fig. S2). However,
there is a large difference in flexibility beyond residue 150,
with greatly increased flexibility in the PD state. This is not
at all surprising, when recalling that it is residues 153–169
that undergo an order-to-disorder transition (Fig. 2).
It should be noted that the last several C-terminal residues
in the ordered simulations do exhibit increased flexibility.
Specifically, it is only residues 166–169 that have RMS fluc-
tuation values >2.5 A˚ in these simulations. Importantly,
NMR and x-ray crystallographic studies of human HABD
constructs, consisting of residues 20–178 and in the absence
of any hyaluronan, noted significant disorder and flexibility
for residues 170–178 (9). Therefore, it is not surprising that
the last few residues of the residue 20–169 construct studiedBiophysical Journal 105(5) 1217–1226here demonstrate some flexibility in the ordered form, given
their close proximity to 170–178.PD-form flexibility allows basic residue side
chains in the C-terminal region to directly
associate with HA8
In the only atomic-resolution structures of HABD com-
plexed with HA (14), the C-terminal residues 153–169 are
in the ordered state. Of these, Arg154, Lys158, and Arg162
have basic side chains, but the side chains of all three are
located >10 A˚ away from the bound carbohydrate (14).
Thus, there is no obvious structural explanation from exist-
ing structural biology for the molecular mechanism by
which the O-to-PD transition enhances binding affinity
(13,15) or why alanine scanning of these residues would
reduce binding affinity (10). Analysis of snapshots from
our PD ABF simulations provides the first structural expla-
nation: in the PD ABF trajectories, the disordered C-termi-
nal residues spontaneously bind to HA.
The PD system as constructed had the Arg154, Lys158, and
Arg162 side chains >10 A˚ from the bound HA. Unlike in the
O state, these residues in the PD state have sufficient confor-
mational flexibility such that, during the course of the 200-
ns ABF MD trajectories, they sample conformational space
to eventually collide with bound HA8. Importantly, unlike
the ABF-induced sampling of the Arg41 loop and side chain,
the conformational sampling of these C-terminal residues is
unbiased, thus all observed association is spontaneous.
Individual analysis for spontaneous association of all
HABD Arg and Lys side chains with hyaluronan in the six
PD ABF trajectories (see Table S1, first column, Wild-
type, partially disordered) shows several of these basic
amino-acid side chains to preferentially bind to hyaluronan.
Residues with >10% spontaneous binding include: Arg78,
Arg90, Arg150, Arg154, Lys158, and Arg162 (see Table S2;
note: Arg41 is excluded from the analysis because its bind-
ing is biased by ABF sampling). Of these, Arg154, Lys158,
and Arg162 are all in the disordered C-terminus of HABD
in the PD state.
Arg154 is particularly notable, as it exhibits 80% binding
following spontaneous association over the course of a 200-
ns trajectory. The initial binding event occurs 40 ns into the
trajectory, and aside from a very brief dissociation event at
Unfolding-Enhanced Binding Mechanism 122370 ns this contact is maintained until the end of the simula-
tion (see Fig. S3). This trajectory highlights two properties
of the disordered C-terminal residues: First, in the absence
of binding with hyaluronan, the C-terminus is very flexible.
This is evidenced by the fluctuation of the minimum contact
distance from <2 A˚ to >17 A˚ and back down to <2 A˚ in a
short 2-ns stretch near the 70-ns mark in the trajectory.
Second, once bound, the interaction is capable of stability
exceeding 100 ns. In fact, the 80% association number for
this trajectory becomes nearly 100%, if the initial 20% of
the trajectory, during which the C-terminal residues are
searching conformational space before making first contact
with hyaluronan, is excluded.
Fig. 4 illustrates the conformation of the complex at the
beginning of this trajectory (Fig. 4 a), at the end of this tra-
jectory (Fig. 4 b), and also the molecular details of the inter-
action at the end of the trajectory (Fig. 4 c). From these
snapshots, it is clear what a large amount of flexibility is
required to enable Arg154 direct contact with HA. Addition-
ally, the stability of the interaction is due to the formation of
two hydrogen bonds involving the positively charged Arg154
side-chain guanidinium group and the negatively charged
GlcUA4 carboxylate group, with atoms from these groupsFIGURE 4 Spontaneous association of Arg154 with hyaluronan in PD
CD44 HABD. (a) First snapshot from the ABF trajectory seeded with
wild-type, partially disordered initial condition 1 (see Table S1 in the Sup-
porting Material). (b) Last snapshot from this trajectory. (c) Close-up of
panel b. (Blue arrows) Pointers to the guanidinium group of the Arg154
side chain. (Red arrow) Pointers to the carboxylate group of GlcUA4.
HABD residues 153–169 are colored by secondary structure. Arg154 and
HA8 are shown as vdW spheres (a and b), or as tube and ball-and-stick
representations, respectively (c).approaching to within 1.7 A˚ of each other (Fig. 4 c). The
lack of sustained spontaneous dissociation following spon-
taneous association in this trajectory implies strong binding
between Arg154 and HA.
Experimental data exist to support the important role of
Arg154 in binding HA. From the simulation data (see Table
S2), all of the basic residues in the disordered C terminus—
namely, Arg154, Lys158, and Arg162—are capable of associ-
ating with bound HA8. In addition, single point mutations to
Ala at each of these residues all reduce binding affinity, as
does truncation of this entire C-terminal region (10). Among
the single point mutations, it is Arg154Ala that has the
largest impact with regard to reducing binding affinity
(10), which is consistent with the leading role Arg154 has
in associating with HA in the simulations (see Table S2).
We note that contradictory experimental evidence exists in
which single point mutants did not have altered binding
affinity (14); however, HA used to generate some of this
contradictory data was conjugated to fluorescein, which
may have interfered with the ability of, e.g., Arg154 to
bind, especially if HA carboxylate groups were used for
the conjugation (51). Our results reinforce the importance
of Arg154 in the binding of HA.The Arg41Ala mutation strongly destabilizes the
B-form complex and therefore HA8 binding
The earliest work aimed at understanding which CD44 res-
idues contributed to HA binding revealed that an Arg41Ala
single point mutation essentially abolished binding (10).
Very recent studies quantitated the effect as reducing
the binding affinity by 2.5 kcal/mol (Kd, wild-type ¼ 20 mm,
Kd, Arg41Ala ¼ 1200 mm) (14). While the atomic resolution
x-ray crystallographic structural studies provide an obvious
explanation for this phenomenon, with the A-to-B transition
allowing direct Arg41 side-chain association with HA8
(Fig. 1), these experimental structures are still indirect evi-
dence because no experimental thermodynamic data exist
to directly show that the A-form is a higher free-energy state
than the B-form, hence the need to perform the experimental
Arg41Ala studies. In contrast, the simulation data directly
demonstrate that the B-form complex is in fact the global
free-energy minimum by a substantial amount relative to
the A-form (Fig. 3, a and b, and Table 1). Similar simulation
data directly demonstrate the B-form complex is strongly
destabilized by the Arg41Ala mutation (Fig. 3, c and d,
and Table 1), further demonstrating the importance of the
direct Arg41 side-chain contact with hyaluronan for strong
binding. We note that, in the simulations, this destabilization
must be a side-chain effect, as the force-field parameters for
the peptide backbone are identical for Arg and Ala (29,30).
In fact, there is quantitative agreement between the exist-
ing experimental data and our simulation data with regard to
the destabilizing effect of the Arg41Ala mutation relative to
the wild-type (WT). From Table 1, DGA-to-B for the orderedBiophysical Journal 105(5) 1217–1226
1224 Favreau et al.Arg41Ala system is 6.5 kcal/mol. Therefore, for the
ordered systems,










in near-exact agreement with the experimental value of
2.5 kcal/mol. Similarly, for the partially disordered systems,









While we cannot discount that this agreement is fortuitous,
because, due to computational expense, the free-energy sur-
faces were not determined in, e.g., triplicate to allow for
estimates of convergence and random error, the time-depen-
dent behavior of the computed free energies does provide
some reassurance of convergence, as detailed below.Systems demonstrate slow convergence of
A-to-B transition free-energies
We end on a cautionary note with regard to the sampling
requirements for obtaining free-energy estimates for this
system. Preliminary work toward obtaining a free-energy
estimate for the A-to-B transition involved umbrella sam-
pling with a bias applied solely to the r coordinate and a
5-ns sampling timescale (21). Based on those efforts, the
conclusion was drawn that the A- and B-forms of the
ordered wild-type HA-bound HABD were essentially equal
in free energy, in stark contrast to our results showing the
B-form to be much more stable. As mentioned previously,
while one possibility is that there is a species dependence
because the prior work utilized mouse HABD, the more
likely explanation is lack of sufficient sampling in the prior
study. Evidence supporting this explanation is the time-
dependent behavior of DGA-to-B. In all four systems studied
here, DGA-to-B exhibits slow convergence relative to the
200-ns timescale of the ABF simulations, with asymptotic
behavior typically not seen until 100 ns or more of sampling
has been reached (see Fig. S4). Once asymptotic behavior is
reached, the fluctuations in the DGA-to-B values suggest a
precision of ~1 kcal/mol (see Fig. S4).
We note that, as computing power continues to become
more readily available, it would be worthwhile to repeat
these computational experiments in, e.g., triplicate to allow
for independent error estimates, because single-experiment
time-dependent ABF error estimates can lead to false reas-
surance that convergence has been achieved (52). Neverthe-
less, these data provide a compelling description—one thatBiophysical Journal 105(5) 1217–1226is consistent with existing experimental data—of the ener-
getics and molecular mechanism by which conformational
changes in HABD enable switching from low-affinity to
high-affinity binding.CONCLUSIONS
Using MD simulations, a clear description of the molecular
mechanisms and associated energetics has been determined
for the conformation-dependent affinity switching of the
CD44:hyaluronan binding interaction. The description is
not only consistent with previous experimental data, but
also resolves the apparent controversy between x-ray
crystallographic and NMR studies, in which the former
correlated affinity switching with a local conformational
change at the binding site (14) and the latter with a dramatic
17-amino-acid, order-to-disorder transition distant from the
binding site (13). In summary, the local change allows for
formation of hydrogen bonds between the binding site
Arg41 side chain and hyaluronan, and this specific interac-
tion is shown here to have highly-favorable energetics.
Furthermore, the order-to-disorder transition enables
increased binding affinity by freeing up basic amino acids
in the disordered region to directly bind hyaluronan, which
they are geometrically unable to do when restrained to their
positions far from the binding in the ordered state. While
there does not appear to be any allosteric coupling between
these two different mechanisms of affinity switching given
the ~1 kcal/mol precision of our results, this does not pre-
clude combined targeting of the two different mechanisms
to inhibit CD44 binding to hyaluronan. Given CD44’s
importance in cell signaling, cell migration, cancer, and
inflammation (1,53–55), the future development of two in-
dependent and complementary classes of small molecule
inhibitors—the first directly occupying the binding site
and the second binding to and stabilizing the ordered form
of the C-terminal residues—is expected to have utility
with regard to novel research tools and potential precursors
to therapeutics.
The molecular mechanism for affinity switching arising
from an order-to-disorder transition detailed here is analo-
gous to a broad class of binding interactions observed in
intrinsically disordered proteins, whose surprising lack of
secondary and tertiary structure is critical to their function
(56). As with CD44 HABD, in these proteins the lack of
such structure confers conformational freedom to amino-
acid residues, and this conformational freedom is critical
to their function as it enables direct association with binding
partners (57,58). Many of the more well-described proteins
in this category become more ordered upon association with
their binding partners, although exceptions exist, with recent
work on p53 showing it to be substantially more disordered
when bound to its partner (59,60). Likewise, it is a more
disordered form of CD44 HABD that preferentially binds
to its partner.
Unfolding-Enhanced Binding Mechanism 1225While our results provide a detailed description of the
molecular mechanism and energetics of changes in the
CD44 protein impacting binding, the biological form of
CD44 is a glycoprotein. That is, CD44 has covalently-
attached carbohydrates (5). These post-translational modifi-
cations are known to modulate the hyaluronan-binding
affinity of CD44 (61–63). The system considered here
lacked these glycosylations; additional studies are presently
underway to study the molecular mechanisms by which
these glycosylations also contribute to modulating the
hyaluronan-binding function of CD44.SUPPORTING MATERIAL
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